Compare Oklo Inc (OKLO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Twist Bioscience Corp — how do they compare? Oklo Inc trades at $42.63 (market cap $7.92B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Oklo Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| OKLO | TWST | |
|---|---|---|
Market Cap | $7.92B | $8.26B |
Sector | Technology | Health |
52-Week High | $174.14 | $153.10 |
52-Week Low | $36.84 | $24.16 |
Enterprise Value | $5.46B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $43.31, up 4.94% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces fundamental challenges, including negative net income margins of -12,625.54% and significant cash burn from operations. Recent news highlights progress in small modular reactor projects but also delays, such as a 14-month setback for its Ohio project noted by Zacks Investment Research on September 1, 2026.
Wall Street maintains a bullish outlook with a $71.58 consensus price target and 71.43% buy ratings, driven by long-term potential in nuclear energy for AI power demand. Key risks include lack of profitability, project execution delays, and high valuation multiples amid substantial cash outflows, requiring careful risk assessment by investors.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
